145 related articles for article (PubMed ID: 27233268)
21. Chikungunya-specific IgG and neutralizing antibody responses in natural infection of Chikungunya virus in children from India.
Verma A; Nayak K; Chandele A; Singla M; Ratageri VH; Lodha R; Kabra SK; Murali-Krishna K; Ray P
Arch Virol; 2021 Jul; 166(7):1913-1920. PubMed ID: 33907861
[TBL] [Abstract][Full Text] [Related]
22. High yield expression and purification of Chikungunya virus E2 recombinant protein and its evaluation for serodiagnosis.
Verma A; Chandele A; Nayak K; Kaja MK; Arulandu A; Lodha R; Ray P
J Virol Methods; 2016 Sep; 235():73-79. PubMed ID: 27180040
[TBL] [Abstract][Full Text] [Related]
23. Monoclonal antibodies specific for the capsid protein of chikungunya virus suitable for multiple applications.
Goh LYH; Hobson-Peters J; Prow NA; Gardner J; Bielefeldt-Ohmann H; Suhrbier A; Hall RA
J Gen Virol; 2015 Mar; 96(Pt 3):507-512. PubMed ID: 25480927
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus.
Kumar M; Sudeep AB; Arankalle VA
Vaccine; 2012 Sep; 30(43):6142-9. PubMed ID: 22884660
[TBL] [Abstract][Full Text] [Related]
25. Structural basis of Chikungunya virus inhibition by monoclonal antibodies.
Zhou QF; Fox JM; Earnest JT; Ng TS; Kim AS; Fibriansah G; Kostyuchenko VA; Shi J; Shu B; Diamond MS; Lok SM
Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27637-27645. PubMed ID: 33087569
[TBL] [Abstract][Full Text] [Related]
26. A chikungunya fever vaccine utilizing an insect-specific virus platform.
Erasmus JH; Auguste AJ; Kaelber JT; Luo H; Rossi SL; Fenton K; Leal G; Kim DY; Chiu W; Wang T; Frolov I; Nasar F; Weaver SC
Nat Med; 2017 Feb; 23(2):192-199. PubMed ID: 27991917
[TBL] [Abstract][Full Text] [Related]
27. Fluorescent Immunosorbent Assay for Chikungunya Virus Detection.
Nguyen HC; Park H; Shin HJ; Nguyen NM; Nguyen ATV; Trinh TT; Duong THY; Tuong HT; Hoang VT; Seo GE; Sohn HJ; Yeo SJ
Intervirology; 2019; 62(3-4):145-155. PubMed ID: 31533104
[TBL] [Abstract][Full Text] [Related]
28. Monoclonal Antibodies as Prophylactic and Therapeutic Agents Against Chikungunya Virus.
Clayton AM
J Infect Dis; 2016 Dec; 214(suppl 5):S506-S509. PubMed ID: 27920182
[TBL] [Abstract][Full Text] [Related]
29. Development of a neutralization assay based on the pseudotyped chikungunya virus of a Korean isolate.
Chung WC; Hwang KY; Kang SJ; Kim JO; Song MJ
J Microbiol; 2020 Jan; 58(1):46-53. PubMed ID: 31768937
[TBL] [Abstract][Full Text] [Related]
30. Luciferase Immunosorbent Assay Based on Multiple E Antigens for the Detection of Chikungunya Virus-Specific IgG Antibodies.
Li X; Wan X; Liu J; Wang H; Li A; Ke C; Tang S; Zhao W; Cai S; Wan C
Microbiol Spectr; 2022 Apr; 10(2):e0149621. PubMed ID: 35311573
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical Detection of Chikungunya Virus Antigens in Formalin-Fixed and Paraffin-Embedded Tissues.
Chiam CW; Sam IC; Chan YF; Wong KT; Ong KC
Methods Mol Biol; 2016; 1426():235-40. PubMed ID: 27233276
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of chikungunya virus infection in children from India during 2009-2010: A cross sectional observational study.
Raghavendhar BS; Ray P; Ratagiri VH; Sharma BS; Kabra SK; Lodha R
J Med Virol; 2016 Jun; 88(6):923-30. PubMed ID: 26581026
[TBL] [Abstract][Full Text] [Related]
33. Characterization of antibody response in patients with acute and chronic chikungunya virus disease.
Anfasa F; Lim SM; Fekken S; Wever R; Osterhaus ADME; Martina BEE
J Clin Virol; 2019 Aug; 117():68-72. PubMed ID: 31229935
[TBL] [Abstract][Full Text] [Related]
34. Pre-existing chikungunya virus neutralizing antibodies correlate with risk of symptomatic infection and subclinical seroconversion in a Philippine cohort.
Yoon IK; Srikiatkhachorn A; Alera MT; Fernandez S; Cummings DAT; Salje H
Int J Infect Dis; 2020 Jun; 95():167-173. PubMed ID: 32247051
[TBL] [Abstract][Full Text] [Related]
35. Virus Isolation and Preparation of Sucrose-Banded Chikungunya Virus Samples for Transmission Electron Microscopy.
Lim CK
Methods Mol Biol; 2016; 1426():153-62. PubMed ID: 27233269
[TBL] [Abstract][Full Text] [Related]
36. Chikungunya virus RNA and antibody testing at a National Reference Laboratory since the emergence of Chikungunya virus in the Americas.
Prince HE; Seaton BL; Matud JL; Batterman HJ
Clin Vaccine Immunol; 2015 Mar; 22(3):291-7. PubMed ID: 25540275
[TBL] [Abstract][Full Text] [Related]
37. Development and Evaluation of an in-House IgM-Capture ELISA for the Detection of Chikungunya and Its Application to a Dengue Outbreak Situation in Kenya in 2013.
Wasonga C; Inoue S; Kimotho J; Morita K; Ongus J; Sang R; Musila L
Jpn J Infect Dis; 2015; 68(5):410-4. PubMed ID: 25866119
[TBL] [Abstract][Full Text] [Related]
38. Molecular characterization of dengue and chikungunya virus strains circulating in New Delhi, India.
Afreen N; Deeba F; Khan WH; Haider SH; Kazim SN; Ishrat R; Naqvi IH; Shareef MY; Broor S; Ahmed A; Parveen S
Microbiol Immunol; 2014 Dec; 58(12):688-96. PubMed ID: 25346397
[TBL] [Abstract][Full Text] [Related]
39. Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus.
Tiwari M; Parida M; Santhosh SR; Khan M; Dash PK; Rao PV
Vaccine; 2009 Apr; 27(18):2513-22. PubMed ID: 19368794
[TBL] [Abstract][Full Text] [Related]
40. Pathogenic Chikungunya Virus Evades B Cell Responses to Establish Persistence.
Hawman DW; Fox JM; Ashbrook AW; May NA; Schroeder KMS; Torres RM; Crowe JE; Dermody TS; Diamond MS; Morrison TE
Cell Rep; 2016 Aug; 16(5):1326-1338. PubMed ID: 27452455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
